About us

Overview


A bold vision for the future of antibody therapeutics.


Through advanced protein engineering, we've developing new generation of antibody-based therapeutics – with an initial focus on TNF receptor (TNFR) agonism and infectious diseases – that influence complex biology in ways that have never been possible.

Our Multabody™ platform brings multiple antibody binding domains together on a three-dimensional scaffold. By tuning how these domains engage and interact with biological targets, we can control the signals and responses that follow.

Pursuing high-value therapeutic opportunities

We are advancing a pipeline of Multabody™ therapeutics including TNFR agonists targeting 4-1BB, the master regulator of T cell durability, and DR5, an unsolved therapeutic target in cancer. Our HIV program is designed to target latent viral reservoirs and deliver broad neutralization.

> SEE OUR PIPELINE

This creates the opportunity to:

Activate receptors to stimulate
desired biological activity.


Inhibit targets or pathways to dampen underlying disease mechanisms.


Coordinate complementary biological mechanisms within a single therapeutic molecule.


> VIEW OUR PLATFORM


While conventional antibodies have transformed medicine, they are limited in their ability to engage complex biological targets. Radiant is going beyond these limitations.